Additionally, immunotherapy targeting EpCaM-expressing cancer stem cells (CSCs) with chimeric antigen receptor (CAR) T cells therapy has been attempted recently in a preclinical model of PCa, which suggests immunotherapy against CSCs is a promising therapeutic strategy for PCa (63). This evidence concerns the gene EPCAM and cancer.